CWA Asset Management Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.7M | Buy |
86,259
+2,945
| +4% | +$634K | 0.66% | 26 |
|
|
2026
Q1 | $18.1M | Sell |
83,314
-290
| -0.3% | -$64.3K | 0.62% | 33 |
|
|
2025
Q4 | $19.1M | Buy |
83,604
+11,964
| +17% | +$2.73M | 0.69% | 29 |
|
|
2025
Q3 | $16.6M | Buy |
71,640
+20,264
| +39% | +$4.13M | 0.61% | 32 |
|
|
2025
Q2 | $9.54M | Buy |
51,376
+1,771
| +4% | +$329K | 0.4% | 55 |
|
|
2025
Q1 | $10.4M | Buy |
49,605
+1,222
| +3% | +$238K | 0.5% | 45 |
|
|
2024
Q4 | $8.6M | Sell |
48,383
-7,268
| -13% | -$1.34M | 0.43% | 55 |
|
|
2024
Q3 | $11M | Buy |
+55,651
| New | +$10.4M | 0.58% | 43 |
|
|
2024
Q1 | $7.69M | Buy |
42,243
+2,528
| +6% | +$436K | 0.47% | 50 |
|
|
2023
Q4 | $6.15M | Buy |
39,715
+12,794
| +48% | +$1.87M | 0.42% | 62 |
|
|
2023
Q3 | $4.01M | Buy |
26,921
+792
| +3% | +$116K | 0.3% | 83 |
|
|
2023
Q2 | $3.52M | Buy |
26,129
+1,122
| +4% | +$165K | 0.24% | 83 |
|
|
2023
Q1 | $3.99M | Buy |
25,007
+923
| +4% | +$141K | 0.3% | 76 |
|
|
2022
Q4 | $3.89M | Buy |
24,084
+517
| +2% | +$79.3K | 0.32% | 78 |
|
|
2022
Q3 | $3.16M | Sell |
23,567
-128
| -0.5% | -$18.4K | 0.31% | 70 |
|
|
2022
Q2 | $3.63M | Sell |
23,695
-36
| -0.2% | -$5.5K | 0.34% | 64 |
|
|
2022
Q1 | $3.85M | Sell |
23,731
-797
| -3% | -$116K | 0.29% | 75 |
|
|
2021
Q4 | $3.32M | Buy |
24,528
+970
| +4% | +$115K | 0.25% | 89 |
|
|
2021
Q3 | $2.54M | Buy |
23,558
+1,443
| +7% | +$165K | 0.2% | 101 |
|
|
2021
Q2 | $2.53M | Sell |
22,115
-347
| -2% | -$39.1K | 0.21% | 97 |
|
|
2021
Q1 | $2.43M | Buy |
22,462
+311
| +1% | +$33.3K | 0.22% | 96 |
|
|
2020
Q4 | $2.37M | Sell |
22,151
-906
| -4% | -$87.1K | 0.25% | 94 |
|
|
2020
Q3 | $2.02M | Buy |
23,057
+11,210
| +95% | +$1.06M | 0.27% | 76 |
|
|
2020
Q2 | $1.16M | Sell |
11,847
-12,778
| -52% | -$1.13M | 0.2% | 75 |
|
|
2020
Q1 | $1.88M | Buy |
24,625
+15,461
| +169% | +$1.32M | 0.36% | 68 |
|
|
2019
Q4 | $811K | Sell |
9,164
-9,081
| -50% | -$754K | 0.13% | 104 |
|
|
2019
Q3 | $1.38M | Sell |
18,245
-2,790
| -13% | -$191K | 0.22% | 87 |
|
|
2019
Q2 | $1.53M | Buy |
21,035
+2,012
| +11% | +$158K | 0.26% | 83 |
|
|
2019
Q1 | $1.53M | Buy |
19,023
+1,530
| +9% | +$125K | 0.3% | 80 |
|
|
2018
Q4 | $1.61M | Buy |
17,493
+351
| +2% | +$30.9K | 0.38% | 69 |
|
|
2018
Q3 | $1.62M | Sell |
17,142
-3,537
| -17% | -$335K | 0.36% | 74 |
|
|
2018
Q2 | $1.92M | Buy |
20,679
+317
| +2% | +$31K | 0.45% | 69 |
|
|
2018
Q1 | $1.93M | Buy |
20,362
+203
| +1% | +$22.3K | 0.47% | 72 |
|
|
2017
Q4 | $1.95M | Buy |
20,159
+130
| +0.6% | +$12.3K | 0.52% | 66 |
|
|
2017
Q3 | $1.78M | Sell |
20,029
-50
| -0.2% | -$3.81K | 0.52% | 68 |
|
|
2017
Q2 | $1.46M | Buy |
20,079
+317
| +2% | +$21.3K | 0.46% | 71 |
|
|
2017
Q1 | $1.29M | Buy |
19,762
+13,914
| +238% | +$875K | 0.44% | 68 |
|
|
2016
Q4 | $366K | Buy |
5,848
+657
| +13% | +$40.1K | 0.16% | 110 |
|
|
2016
Q3 | $327K | Sell |
5,191
-5,670
| -52% | -$367K | 0.18% | 99 |
|
|
2016
Q2 | $672K | Buy |
10,861
+557
| +5% | +$33.9K | 0.41% | 71 |
|
|
2016
Q1 | $589K | Buy |
10,304
+5,076
| +97% | +$283K | 0.6% | 50 |
|
|
2015
Q4 | $310K | Buy |
+5,228
| New | +$301K | 0.35% | 100 |
|
Other funds holding ABBV
CWA Asset Management Group's ABBV Position: Q2 2026 in Review
CWA Asset Management Group increased its AbbVie (ABBV) stake by 3.5% in Q2 2026, buying an estimated $634K and bringing the position to 86,259 shares worth $21.7M. The position accounts for 0.66% of the portfolio, ranked #26.
CWA Asset Management Group first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- CWA Asset Management Group held 86,259 shares of AbbVie worth $21.7M as of Q2 2026.
- CWA Asset Management Group bought 2,945 AbbVie shares in Q2 2026, an estimated $634K.
- AbbVie made up 0.66% of CWA Asset Management Group's portfolio in Q2 2026, its #26 holding.
- CWA Asset Management Group first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
- 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on CWA Asset Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.